ValuEngine upgraded shares of icad inc. (NASDAQ:ICAD) from a strong sell rating to a sell rating in a report released on Monday morning.

Separately, Laidlaw restated a buy rating and set a $11.00 target price on shares of icad inc. in a research note on Tuesday, July 25th.

icad inc. (NASDAQ:ICAD) traded up 0.7478% during trading on Monday, hitting $4.5135. 11,524 shares of the stock traded hands. icad inc. has a 12 month low of $2.82 and a 12 month high of $6.07. The company’s market cap is $74.90 million. The company’s 50 day moving average price is $3.80 and its 200 day moving average price is $4.34.

icad inc. (NASDAQ:ICAD) last posted its earnings results on Tuesday, August 8th. The technology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The firm had revenue of $6.41 million during the quarter, compared to analysts’ expectations of $6.41 million. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. On average, equities research analysts anticipate that icad inc. will post ($0.54) EPS for the current fiscal year.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/icad-inc-icad-raised-to-sell-at-valuengine/1610252.html.

In other icad inc. news, Director Dr Lawrence Howard bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was purchased at an average price of $3.33 per share, for a total transaction of $33,300.00. Following the completion of the purchase, the director now directly owns 488,022 shares in the company, valued at $1,625,113.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 19.10% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the stock. Argent Capital Management LLC lifted its stake in icad inc. by 13.2% during the second quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock worth $2,990,000 after purchasing an additional 82,967 shares during the last quarter. Vanguard Group Inc. lifted its stake in icad inc. by 0.4% during the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock worth $1,912,000 after purchasing an additional 2,007 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in icad inc. by 822.3% during the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock worth $586,000 after purchasing an additional 124,612 shares during the last quarter. Hedge funds and other institutional investors own 23.74% of the company’s stock.

icad inc. Company Profile

iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.